The U.S. Department of Defense's Defense Health Agency awarded a $526,042 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to support research aimed at identifying and targeting mechanisms of prostate cancer therapy resistance driven by the tumor microenvironment. The project will be conducted over a 2-year period from May 1, 2024 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). This research grant is intended to advance understanding of how the tumor microenvironment contributes to prostate cancer treatment resistance and develop new therapeutic approaches to overcome this challenge, with the goal of improving outcomes for military service members and the broader patient population.
Generated 1/14/25, 4:35 AM